Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Gilead Sciences Inc | 101 |
| 2 | Clearside Biomedical Inc | 67 |
| 3 | Senju Pharmaceutical Co Ltd | 58 |
| 4 | Institució Catalana de Recerca i Estudis Avançats | 43 |
| 5 | UVA Licensing and Ventures Group | 37 |
| 6 | Genentech Inc | 26 |
| 7 | Rohto Pharmaceutical Co Ltd | 23 |
| 8 | Alcon Inc | 21 |
| 9 | Ascendis Pharma AS | 21 |
| 10 | Kala Bio Inc | 20 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 969 |
| 2 | A61P | Therapeutic activity (drug indications) | 890 |
| 3 | C07K | Peptides | 244 |
| 4 | C07D | Heterocyclic compounds | 218 |
| 5 | G01N | Investigating / analysing materials | 162 |
| 6 | C12Q | Measuring/testing involving enzymes | 125 |
| 7 | A61M | Devices for introducing media into the body | 94 |
| 8 | A61F | 85 | |
| 9 | C07C | Acyclic and carbocyclic compounds | 85 |
| 10 | C12N | Microorganisms, enzymes | 62 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWhere research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Inflammatory mediators and NSAID effects | 3 |
| 2 | Coagulation, Bradykinin, Polyphosphates, and Angioedema | 2 |
| 3 | Anesthesia and Pain Management | 1 |
| 4 | Glaucoma and retinal disorders | 1 |
| 5 | Ocular Surface and Contact Lens | 1 |
| 6 | Retinal Diseases and Treatments | 1 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | James A. Gow | Spectrum Pharmaceuticals (United States) | 7 |
| 2 | L. David Waterbury | Emergent BioSolutions (Canada) | 6 |
| 3 | Frank A. Bucci | Bucci Laser Vision Institute | 5 |
| 4 | Joan Korth‐Bradley | Women's Health Research Institute | 5 |
| 5 | Sheryl DeCleene | Women's Health Research Institute | 5 |
| 6 | James A. Forbes | Johns Hopkins University | 4 |
| 7 | Nina R. Shah | 2 | |
| 8 | Timothy R. McNamara | Spectrum Pharmaceuticals (United States) | 4 |
| 9 | William H. Cevallos | Women's Health Research Institute | 4 |
| 10 | Curtis R. Kelly | Alcon (United States) | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Drug-Induced Hepatotoxicity | 2003 | 1580 | Pharmacogenetics and Drug Metabolism |
| The Safety of Newly Approved Medicines | 1999 | 241 | Pharmaceutical Economics and Policy |
| European multicenter trial of the prevention of cystoid macular edema after cataract surgery in nondiabetics: ESCRS PREMED study report 1 | 2018 | 152 | Retinal Diseases and Treatments |
| Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium | 2006 | 111 | Synthesis and biological activity |
| A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data | 1994 | 109 | Computational Drug Discovery Methods |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the chemical composition and molecular weight of XiDay?
Which organizations hold the most patents for XiDay?
What are the primary research topics associated with XiDay?
What is the publication and patent activity trend for XiDay in recent years?
Who are the most prolific authors publishing research on XiDay?